Skip to main content
OpenTrials
Completed

NCT Number: NCT01452906

A Drug-Drug Interaction Study of Omeprazole and PA21

The purpose of this study is to determine if Omeprazole is affected by PA21.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Healthy

Age range

20 year–50 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1

Primary location

ACRI - Phase 1

Anaheim, California, 92801, United States

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Healthy Volunteers
  • Written informed consent

Exclusion criteria

  • No significant medical conditions
  • Pregnancy

Treatment and study plan

PA21 and Omeprazole with food

Drug

The maximum dose of PA21 will be 15.0 g/day. The maximum dose of Omeprazole will be 40 mg/day

No PA21; Omeprazole with food

Drug

The maximum dosage of Omeprazole will be 40 mg/day

PA21 with food, Omeprazole 2hrs later

Drug

The maximum dose of PA21 will be 15 g/day. The maximum dose of Omeprazole will be 40 mg/day

Primary outcomes

  1. Area Under the Curve from time zero to 24 hours (AUC0-24)

    Time frame: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24 hours post omeprazole dose on Days 0, 11, 22

    Area under the plasma concentration versus time curve from time zero (pre-dose) to 24 hours

  2. Area Under the Curve from time zero to infinite (AUC0-infinity)

    Time frame: pre-dose, 0.25, 0.5, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48 hours post omeprazole dose on days 0, 11, 22

    Area under the plasma concentration versus time curve from time zero (pre-dose) to extrapolated infinite time

  3. Maximum observed plasma concentration (Cmax)

    Time frame: pre-dose, 0.25, 1, 1.5, 2, 2.5, 3, 3.5, 4, 5, 6, 8, 12, 24, 48 hours post omeprazole dose on days 0, 11, 22

Sponsors and collaborators

Lead sponsor

Vifor Pharma

Industry

Registry information

Official study title

A Single-centre, Open-label, Three-period Study of the Pharmacokinetic Effect of PA21 on Omeprazole in Healthy Male and Female Adults

Important dates

Study start
2011
Primary completion
2011
Study completion
2011
First posted
Oct 17, 2011
Registry last updated
Dec 12, 2011

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.